<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>国广有话说 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2021-01-13T12:04:36+08:00</updated>
  <subtitle>立足于客观公正，挖掘发现医药企业价值投资机会</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>2020年疫苗行业批签发专题报告： 大品种持续放量，行业持续高景气【东吴医药朱国广团队】</title>
    <updated>2021-01-13T09:38:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-13:/s/2KVnMlbJqaVFKFdYiOBdLA</id>
    <link href="https://mp.weixin.qq.com/s/2KVnMlbJqaVFKFdYiOBdLA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>创新药持续火热，重点推荐恒瑞医药、信达生物等！【东吴医药朱国广团队|0109周报】</title>
    <updated>2021-01-10T17:18:57+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-10:/s/mQqtcHmEPFmW-ocgRfUKgQ</id>
    <link href="https://mp.weixin.qq.com/s/mQqtcHmEPFmW-ocgRfUKgQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>信达生物深度：创新药管线布局前瞻，肿瘤免疫疗法行业龙头！【东吴医药朱国广团队】</title>
    <updated>2021-01-08T09:16:02+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-08:/s/mTIxPKQPnn19qHDScpU2oQ</id>
    <link href="https://mp.weixin.qq.com/s/mTIxPKQPnn19qHDScpU2oQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>惠泰医疗新股报告：心脏电生理龙头，血管介入业务加速成长！【东吴医药朱国广团队】</title>
    <updated>2021-01-07T00:17:03+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-07:/s/HxPnCif5KpyKM_Ji9Zhlmw</id>
    <link href="https://mp.weixin.qq.com/s/HxPnCif5KpyKM_Ji9Zhlmw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>医药高端制造系列报告一：中国制造崛起，特色原料药受益显著！【东吴医药朱国广团队】</title>
    <updated>2021-01-06T17:09:33+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-06:/s/BsPVWTQvPQU1rd2qZn5c-A</id>
    <link href="https://mp.weixin.qq.com/s/BsPVWTQvPQU1rd2qZn5c-A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>美诺华深度：22倍估值+未来三年高增长+CDMO布局提估值【东吴医药朱国广团队】</title>
    <updated>2021-01-05T09:17:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-05:/s/EhvZyx8FyDe-m0VwLcKmow</id>
    <link href="https://mp.weixin.qq.com/s/EhvZyx8FyDe-m0VwLcKmow" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>恒瑞医药深度报告：全球视野下的创新工匠！【东吴医药朱国广团队】</title>
    <updated>2021-01-04T16:09:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-04:/s/PgCXuWOOX27XDxaoQHjX8g</id>
    <link href="https://mp.weixin.qq.com/s/PgCXuWOOX27XDxaoQHjX8g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2021年，医药再启程！【东吴医药朱国广团队|0102周报】</title>
    <updated>2021-01-03T18:07:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-03:/s/JBmdDjSFihsQIUC2S3gdBw</id>
    <link href="https://mp.weixin.qq.com/s/JBmdDjSFihsQIUC2S3gdBw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>美诺华（603538）：产能爬坡和新产品获批推动API高增长，制剂一体化+CDMO兑现加速【东吴医药朱国广团队】</title>
    <updated>2020-12-31T13:25:46+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-31:/s/-0RNBovpaOjot_XjnZLc7Q</id>
    <link href="https://mp.weixin.qq.com/s/-0RNBovpaOjot_XjnZLc7Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>恒瑞医药怒涨30%，对国内创新药意味着什么？【东吴医药朱国广团队|1227周报】</title>
    <updated>2020-12-27T17:28:25+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-27:/s/OOlBLn07u9v1jFpSjKcHvA</id>
    <link href="https://mp.weixin.qq.com/s/OOlBLn07u9v1jFpSjKcHvA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>